DHL Group has announced the expansion of DHL Health Logistics Singapore through the development of a €10 million pharmaceutical hub, reinforcing life sciences and healthcare logistics infrastructure in the region.
The investment strengthens DHL Health Logistics Singapore as demand grows for secure, compliant logistics that support increasingly complex global healthcare supply chains. Singapore’s biomedical sector produces goods valued at nearly S$38 billion, requiring infrastructure capable of handling high volumes of temperature-sensitive and regulated products.
Timely delivery and quality assurance are critical components within every link of today’s healthcare supply chain. Whether shipping pharmaceuticals or transporting medical devices, efficient handling, temperature controls and compliance standards affect patient care and research initiatives. DHL’s enhanced capabilities support Singapore as a distribution hub for life sciences products across the region.
DHL’s international network reaches over 220 countries and territories and can facilitate healthcare shipments from anywhere in the world using DHL’s GDP- and GMP-compliant facilities. DHL Health Logistics offers a healthcare-specific warehouse, medical courier network and certified experts who can manage your temperature-sensitive shipments.
The new pharmaceutical hub near Tuas Biomedical Park features specialised temperature zones and GMP-compliant infrastructure, offering strong connectivity to Changi Airport and Tuas Mega Port. The facility forms part of DHL Group’s broader €500 million regional investment plan in health logistics through 2030.
Segments covered by DHL Health Logistics services span pharmaceutical logistics for vaccines and pharmaceuticals, clinical logistics for investigational medicinal products (IMP) and medical device logistics, which includes last-mile delivery and aftermarket services. It also handles shipments of speciality pharmaceuticals that require ambient, chilled, frozen, refrigerated, temperature-controlled and cryogenic shipments. Other areas of support include consumer healthcare fulfilment and humanitarian health logistics.
Operating a wider footprint across healthcare segments enables DHL to better address the goals set out in its DHL Group Strategy 2030. The conglomerate’s new strategy is built around specialised infrastructure, digitalisation and resilience in supply chains worldwide. The ramping up of healthcare capacity in Singapore will help DHL safely and efficiently ship life science products and provide continuity to health system
